Biodesix, Inc. is classed by the SEC under Services-Medical Laboratories (industry code 8071), based in Louisville, CO. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $88 million and a loss of $35 million (its filed statements).
Usage businessServices-Medical LaboratoriesLouisville, COfilings since 20088 of 9 filed, 1 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a usage business: prior from its industry code (SEC 8071, Services-Medical Laboratories); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 4.6 out of ten, 8 of 9 metrics filed and 1 estimated: past 4.1 out of ten, present 4.6 out of ten, future 5.0 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 1.7 out of ten. 1 warning event since 2017; the latest 2025-03-28. 17th percentile among 27 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 3.1 out of ten. +23.8% a year over 7 filed years; profitable in 0 of 7. 32nd percentile among 23 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 9.8 out of ten. CrossAssetData estimate 9.8/10, confidence 35 of 100 (one part). 98th percentile among 24 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Financial health (present): 2.8 out of ten. Leverage 103%: owes 103¢ per asset dollar. 28th percentile among 25 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 4.8 out of ten. bottom 48% of 23 in its family; net margin -39.8%. 48th percentile among 23 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 7.1 out of ten. top 29% of 17 in its family for leadership; chief executive since 2020. 71st percentile among 17 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
Room to expand (future): 2.0 out of ten. bottom 20% of 23 in its family for room to expand. 20th percentile among 23 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 5.5 out of ten. top 45% of 23 in its family for growth drivers. 55th percentile among 23 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 6.3 out of ten. top 37% of 20 in its family for expectations against reality. 63rd percentile among 20 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-02-26 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-05 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-05 (on EDGAR). Newest filing: Form 4, 2026-10-02. Filings on record since 2008. Read from EDGAR 2026-10-12.
Where the revenue comes from
Product and service lines in fiscal 2025: Diagnostic Tests 90%, Development Services 11%. As tagged in its annual report (Form 10-K, filed 2026-02-26).
Who runs it
Hutton, Scott (President & CEO); Patience, John (Chairman); Cowie, Robin Harper (CFO, Sec'y & Treasurer); O'Kane, Kieran (Chief Commercial Officer); Pestano, Gary Anthony (Chief Development Officer); Vazquez, Chris (Chief Accounting Officer); Schuler, Jack W (director); Franchi, Jean M. (director); Kayyem, Jon Faiz (director); Kennedy, Lawrence T. Jr (director); and 2 more. 12 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-10-02.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.